Trends in inflammatory bowel disease infections and vaccinations in the past four decades: A high-level text mining analysis of PubMed publications

References

• Love JR, Irvine EJ, Fedorak RN. Quality of life in IBD. J Clin Gastroenterol. 1992;14:15–6. doi:10.1097/00004836-199201000-00005.
   PubMed Web of Science ®Google Scholar
• Casellas F, Arenas JI, Baudet JS, Fábregas S, García N, Gelabert J, Medina C, Ochotorena I, Papo M, Rodrigo L, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005;11:488–96. doi:10.1097/01.MIB.0000159661.55028.56.
   PubMed Web of Science ®Google Scholar
• Rubin GP, Hungin AP, Chinn DJ, Dwarakanath D. Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Aliment Pharmacol Ther. 2004;19:529–35. doi:10.1111/j.1365-2036.2004.1873.x.
   PubMed Web of Science ®Google Scholar
• Casellas F, López-Vivancos J, Badia X, Vilaseca J, Malagelada J-R. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol. 2001;13:567–72. doi:10.1097/00042737-200105000-00017.
   PubMed Web of Science ®Google Scholar
• Canavan C, Abrams KR, Hawthorne B, Drossman D, Mayberry JF. Long-Term prognosis in Crohn’s disease: factors that affect quality of life. Aliment Pharmacol Ther. 2006;23:377–85. doi:10.1111/j.1365-2036.2006.02753.x.
   PubMed Web of Science ®Google Scholar
• Latella G. Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol. 2012 Aug 7;18(29):3790–99. doi:10.3748/wjg.v18.i29.3790.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Fina D, Caruso R, Pallone F. New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol. 2006;22(4):361–64. doi:10.1097/01.mog.0000231808.10773.8e.
   PubMed Web of Science ®Google Scholar
• Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28(1):573–621. doi:10.1146/annurev-immunol-030409-101225.
   PubMed Web of Science ®Google Scholar
• Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res. 2019 Dec 1;2019:7247238. doi:10.1155/2019/7247238. PMID: 31886308; PMCID: PMC6914932.
   PubMed Web of Science ®Google Scholar
• Chudy-Onwugaje KO, Christian KE, Farraye FA, Cross RK. A State-of-the-Art review of new and emerging therapies for the treatment of IBD. Inflamm Bowel Dis. 2019 Apr 11;25(5):820–30.
   PubMed Web of Science ®Google Scholar
• Klang E, Barash Y, Soffer S, Shachar E, Lahat A. Trends in inflammatory bowel disease treatment in the past two decades-a high-level text mining analysis of PubMed publications. United European Gastroenterol J. 2021 Nov;9(9):1019–26. Epub 2021 Aug 25. doi:10.1002/ueg2.12138. PMID: 34431607; PMCID: PMC8598961.
   PubMed Web of Science ®Google Scholar
• Borman ZA, Côté-Daigneault J, Colombel JF. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1101–08. doi:10.1080/17474124.2018.1530983.
   PubMed Web of Science ®Google Scholar
• Thuraisingham B. Data mining: technologies, techniques, tools, and trends. Boca Raton: CRC Press; 2014.
   Google Scholar
• Song M, Kim SY. Detecting the knowledge structure of bioinformatics by mining full-text collections. Scientometrics. 2013;96:183–201. doi:10.1007/s11192-012-0900-9.
   Web of Science ®Google Scholar
• Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014 Jun;8(6):443–68. Epub 2014 Mar 6. doi:10.1016/j.crohns.2013.12.013.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Baert F. New strategies in the management of inflammatory bowel disease. Acta Clin Belg. 1999 Oct;54(5):274–80. doi:10.1080/17843286.1999.11754245.
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, D’-Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, et al. STRIDE-II: an Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570–83. doi:10.1053/j.gastro.2020.12.031.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Rahier JF, Kirchgesner J. Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020 May;18(6):1324–35. doi:10.1016/j.cgh.2020.02.009.
   PubMed Web of Science ®Google Scholar
• Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018 Aug;155(2):337–46. doi:10.1053/j.gastro.2018.04.012.
   PubMed Web of Science ®Google Scholar
• Windsor JW, Kaplan GG. Evolving epidemiology of IBD. Curr Gastroenterol Rep. 2019 Jul 23;21(8):40. doi:10.1007/s11894-019-0705-6.
   PubMedGoogle Scholar
• Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 Oct 11;345(15):1098–104. doi:10.1056/NEJMoa011110.
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012 Dec;61(12):1693–700. doi:10.1136/gutjnl-2011-301668.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Panes J. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017 Aug 3;377(5):496–97.
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Dec;68(Suppl 3):s1–s106. Epub 2019 Sep 2. doi:10.1136/gutjnl-2019-318484.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, D’-Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun;60(6):780–87. doi:10.1136/gut.2010.221127.
   PubMed Web of Science ®Google Scholar
• Udalova I, Monaco C, Nanchahal J, Feldmann M, Gordon S. Anti-TNF therapy. Microbiol Spectr. 2016 Aug;4(4). doi:10.1128/microbiolspec.MCHD-0022-2015
   PubMed Web of Science ®Google Scholar